Abstract
Immune therapeutics are revolutionizing cancer treatments. In tandem, new and confounding imaging characteristics have appeared that are distinct from those typically seen with conventional cytotoxic therapies. In fact, only 10% of patients on immunotherapy may show tumor shrinkage, typical of positive responses on conventional therapy. Conversely, those on immune therapies may initially demonstrate a delayed response, transient enlargement followed by tumor shrinkage, stable size, or the appearance of new lesions. New imaging response criteria such as the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) and immune-related Response Criteria (irRC) are being implemented in many trials. However, FDA approval of emerging therapies including immunotherapies still relies on the current RECIST criteria. In this review, we review the traditional and new imaging response criteria for evaluation of solid tumors and briefly touch on some of the more commonly associated immunotherapy-induced adverse events.
This is a preview of subscription content, log in via an institution to check access.
References
Kwak JJ, et al. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015;35(2):424–37.
Nishino M, et al. Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur J Radiol. 2015;84(7):1259–68.
Okada H, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–42.
Wolchok JD, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.
Tirkes T, et al. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics. 2013;33(5):1323–41.
Miller AB, et al. Reporting results of cancer treatment. Cancer. 1981;47(1):207–14.
Organization, W.H. WHO handbook for reporting results of cancer treatment; 1979.
Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Bruix J, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the study of the liver. J Hepatol. 2001;35(3):421–30.
Llovet JM, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711.
Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38(Suppl 5):S60–5.
Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol. 2006;9(3):125–32.
Wahl RL, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122s–50s.
Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009;15(23):7116–8.
Nishino M, et al. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014;2:17.
Aarntzen EH, et al. In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cell Mol Life Sci. 2013;70(13):2237–57.
Srishti Abrol GT, Hassan A, Kotrotsou A, Alfaro-Munoz KD, de Groot JF, Zinn P, Colen RR. Radiomics differentiate between true progression and pseudo-progression in GBM patients. In: Annual meeting of the American society of neuroradiology—ASNR, Washington, DC; 2016.
Weber JS, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675–82.
Barjaktarevic IZ, et al. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest. 2013;143(3):858–61.
Bronstein Y, et al. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol. 2011;197(6):W992–w1000.
Takeo Fujii RRC, Bilen AM, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Stephen B, Janku F, Subbiah V, Kato S, Karp DD, Piha-Paul SA, Tsimberidou AM, Fu S, Sharma P, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events in patients who received immunotherapy and radiographic analysis to predict pneumonitis in EORTC-NCI-AACR molecular targets and cancer therapeutics symposium, Munich, Germany; 2016.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Eleneen, Y., Colen, R.R. (2017). Cancer Imaging in Immunotherapy. In: Naing, A., Hajjar, J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 995. Springer, Cham. https://doi.org/10.1007/978-3-319-53156-4_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-53156-4_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-53155-7
Online ISBN: 978-3-319-53156-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)